Skip to content
All news
Analysis

3 Reasons TMO Stock Is Risky and 1 Alternative to Buy

Thermo Fisher shares fell 17.4% over six months to $464.50, underperforming the S&P 500's 10.9% gain. We highlight three risk factors and suggest one alternative investment.

June 18, 2026
2 min read
Source: StockStory
Share:

Key Numbers

current price
$464.50
six month return
-17.4%
s&p 500 return
+10.9%

Thermo Fisher Scientific (TMO) shares have dropped 17.4% over the past six months to $464.50, a stark contrast to the S&P 500's 10.9% gain. This disappointing performance may have investors reconsidering their positions.

3 Reasons TMO Is Risky

1. Underperformance vs. Market

The stock has significantly lagged the broader market, indicating potential structural issues or loss of investor confidence.

2. Sector Headwinds

The healthcare sector faces regulatory pressures and pricing challenges, impacting companies like Thermo Fisher that rely on lab equipment and reagents.

3. Demand Volatility

Demand for the company's products may be unstable, especially after the COVID-19 pandemic peak that previously boosted sales.

One Stock to Buy Instead

Instead of TMO, investors might consider another healthcare stock with stronger performance and greater diversification. (The source did not specify the alternative stock name.)

Conclusion

Investors should carefully assess TMO's risks before making decisions, considering available alternatives in the market.

Frequently Asked Questions

The stock declined due to underperformance vs. the market, sector headwinds, and demand volatility post-COVID-19.

Found this useful? Share it

Share:
This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.